Fig. 2From: The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with 223Ra: first in human studyBehavior of markers of disease burden (ALP and PSA) and haematopoietic impairment (HB, PLT, RBC, WBC) before of each 223Ra administration. Values are reported as symbols, while lines are used only to connect all the patient values. Numbers indicate the enrolled patientsBack to article page